Full Press Release Details
European Commission Grants Marketing Authorization for Leqembi® (lecanemab).
BIIB
European Commission Grants Marketing Authorization for Leqembi® (lecanemab)
Key Takeaway: European Commission Grants Marketing Authorization for Leqembi® (lecanemab)
Price reaction · baseline $119.26 (2025-04-14 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
-1.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis